Programmed Cell Death 1 Receptor
"Programmed Cell Death 1 Receptor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An inhibitory T-lymphocyte receptor that has specificity for CD274 ANTIGEN and PROGRAMMED CELL DEATH 1 LIGAND 2 PROTEIN. Signaling by the receptor limits T cell proliferation and INTERFERON GAMMA synthesis. The receptor also may play an essential role in the regulatory pathway that induces PERIPHERAL TOLERANCE.
Descriptor ID |
D061026
|
MeSH Number(s) |
D12.776.543.750.705.222.875 D23.050.301.264.894.790 D23.101.100.894.790
|
Concept/Terms |
Programmed Cell Death 1 Receptor- Programmed Cell Death 1 Receptor
- PD-1 Receptor
- PD 1 Receptor
- Receptor, PD-1
- CD279 Antigen
- Antigen, CD279
- PD1 Receptor
- Receptor, PD1
- Programmed Cell Death 1 Protein
- Antigens, CD279
- CD279 Antigens
|
Below are MeSH descriptors whose meaning is more general than "Programmed Cell Death 1 Receptor".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptors, Immunologic [D12.776.543.750.705]
- Costimulatory and Inhibitory T-Cell Receptors [D12.776.543.750.705.222]
- Programmed Cell Death 1 Receptor [D12.776.543.750.705.222.875]
- Biological Factors [D23]
- Antigens [D23.050]
- Antigens, Surface [D23.050.301]
- Antigens, Differentiation [D23.050.301.264]
- Antigens, Differentiation, T-Lymphocyte [D23.050.301.264.894]
- Programmed Cell Death 1 Receptor [D23.050.301.264.894.790]
- Biomarkers [D23.101]
- Antigens, Differentiation [D23.101.100]
- Antigens, Differentiation, T-Lymphocyte [D23.101.100.894]
- Programmed Cell Death 1 Receptor [D23.101.100.894.790]
Below are MeSH descriptors whose meaning is more specific than "Programmed Cell Death 1 Receptor".
This graph shows the total number of publications written about "Programmed Cell Death 1 Receptor" by people in this website by year, and whether "Programmed Cell Death 1 Receptor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2003 | 0 | 2 | 2 |
2004 | 0 | 3 | 3 |
2008 | 0 | 1 | 1 |
2009 | 0 | 1 | 1 |
2010 | 0 | 3 | 3 |
2011 | 0 | 1 | 1 |
2013 | 1 | 1 | 2 |
2014 | 2 | 2 | 4 |
2015 | 2 | 3 | 5 |
2016 | 2 | 5 | 7 |
2017 | 4 | 5 | 9 |
2018 | 7 | 5 | 12 |
2019 | 6 | 15 | 21 |
2020 | 9 | 4 | 13 |
2021 | 3 | 7 | 10 |
2022 | 0 | 10 | 10 |
2023 | 2 | 3 | 5 |
2024 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Programmed Cell Death 1 Receptor" by people in Profiles.
-
Tissue-infiltrating alloreactive T cells require Id3 to deflect PD-1-mediated immune suppression during GVHD. Blood. 2024 Jan 11; 143(2):166-177.
-
Nivolumab for Patients With High-Risk Oral Leukoplakia: A Nonrandomized Controlled Trial. JAMA Oncol. 2024 Jan 01; 10(1):32-41.
-
The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial. Nat Med. 2023 Nov; 29(11):2814-2824.
-
A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma. Ann Hematol. 2024 Jan; 103(1):185-198.
-
PD-1 maintains CD8 T cell tolerance towards cutaneous neoantigens. Nature. 2023 Jul; 619(7968):151-159.
-
Eganelisib, a First-in-Class PI3K? Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial. Clin Cancer Res. 2023 06 13; 29(12):2210-2219.
-
TIGIT is a key inhibitory checkpoint receptor in lymphoma. J Immunother Cancer. 2023 06; 11(6).
-
Checkpoint Blockade-Induced Dermatitis and Colitis Are Dominated by Tissue-Resident Memory T Cells and Th1/Tc1 Cytokines. Cancer Immunol Res. 2022 10 04; 10(10):1167-1174.
-
Immune checkpoint inhibitors as neoadjuvant therapy in early triple-negative breast cancer: A systematic review and meta-analysis. J Cancer Res Ther. 2022 Oct-Dec; 18(6):1754-1765.
-
TP53/PLCG2-mutated diffuse large B-cell lymphoma richter transformation (DLBCL-RT) of CLL with unusual CD2 and PD-1 expression. Leuk Lymphoma. 2022 11; 63(11):2735-2738.